224 related articles for article (PubMed ID: 10397751)
1. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
Krijanovski OI; Hill GR; Cooke KR; Teshima T; Crawford JM; Brinson YS; Ferrara JL
Blood; 1999 Jul; 94(2):825-31. PubMed ID: 10397751
[TBL] [Abstract][Full Text] [Related]
2. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury.
Panoskaltsis-Mortari A; Taylor PA; Rubin JS; Uren A; Welniak LA; Murphy WJ; Farrell CL; Lacey DL; Blazar BR
Blood; 2000 Dec; 96(13):4350-6. PubMed ID: 11110712
[TBL] [Abstract][Full Text] [Related]
3. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
[TBL] [Abstract][Full Text] [Related]
4. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Panoskaltsis-Mortari A; Lacey DL; Vallera DA; Blazar BR
Blood; 1998 Nov; 92(10):3960-7. PubMed ID: 9808590
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
6. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
[TBL] [Abstract][Full Text] [Related]
7. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
8. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Reddy P; Maeda Y; Hotary K; Liu C; Reznikov LL; Dinarello CA; Ferrara JL
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3921-6. PubMed ID: 15001702
[TBL] [Abstract][Full Text] [Related]
13. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
14. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
15. Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299.
Annat J; Churaqui E; Dutartre P; Bruley-Rosset M
Transplantation; 1996 Sep; 62(6):721-9. PubMed ID: 8824467
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
Sykes M; Harty MW; Szot GL; Pearson DA
Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
[TBL] [Abstract][Full Text] [Related]
18. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
19. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD.
Yang YG; Sykes M
Leuk Lymphoma; 1999 May; 33(5-6):409-20. PubMed ID: 10342569
[TBL] [Abstract][Full Text] [Related]
20. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]